News | June 17, 2013

Valtech Cardio Treats First Mitral Regurgitation Patients With Percutaneous Annuloplasty

Valtech Cardio Heart Valve Repair Cardioband Annuloplasty Ring

June 17, 2013 — Valtech Cardio Ltd. announced that two patients diagnosed with severe mitral regurgitation (MR) have been treated successfully with its Transfemoral Cardioband Annuloplasty System.

The Cardioband device replaces the need for open-heart surgery for MR patients. The device is implanted without stopping the patient's heart from beating and without putting the patient on a cardiac bypass machine. Another advantage is that the size of the Cardioband can be adjusted while the heart is beating to optimize the results of the repair. Importantly, the form and clinical function of the Cardioband closely replicates that of the annuloplasty rings that are today the standard-of-care in surgery.

The first patients were treated at the San Raffaele Hospital, Milan, Italy. They were selected by the heart team led by Professor Ottavio Alfieri, head of the division of cardiac surgery and Professor Antonio Colombo, head of the division of cardiology. The procedure was performed by Dr. Francesco Maisano.

Following a short, fully percutaneous procedure, the Transfemoral Cardioband Annuloplasty System reduced the degree of the mitral regurgitation from severe to mild. The patients were discharged 48-72 hours after the intervention and follow-up after 30 days indicated that they were continuing to do well.

"Implanting the Cardioband is a straightforward intervention that can become a routine procedure," said Maisano.

Colombo commented, "The Cardioband system preserves the option for future percutaneous or surgical valve replacement, which makes it the ideal first-line interventional therapy."

"The Cardioband system provides an excellent alternative for patients who are considered at high risk for surgery," said Alfieri.

The cases were presented by Maisano at the EuroPCR conference and the Transcatheter Valve Therapies (TVT) in Vancouver, Canada.

"Being able to deliver the surgical gold standard solution, via a transfemoral approach is a major milestone," stated Amir Gross, founder and chief operating officer of Valtech Cardio. "We are very pleased to see these successful outcomes and are now preparing to undertake implantations at major heart centers in Germany and France."

A multi-center study is currently ongoing in leading European centers to study the safety and efficacy of the Transfemoral Cardioband Annuloplasty System in patients suffering from functional mitral regurgitation who are at high risk to undergo surgery.

For more information:

Related Content

Boston Scientific Exercises Option to Acquire Millipede Inc.
News | Annuloplasty Rings | January 02, 2019
Boston Scientific Corp. exercised its option to acquire the remaining shares of Millipede Inc, a privately-held company...
LivaNova Receives FDA Clearance for Memo 4D Semi-Rigid Mitral Annuloplasty Ring
Technology | Annuloplasty Rings | June 15, 2018
LivaNova PLC announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Memo 4D semi-rigid...
Second Micro Interventional Devices Annuloplasty System Successfully Implanted
News | Annuloplasty Rings | October 30, 2017
Micro Interventional Devices Inc. (MID) recently announced the second successful implantation of its MIA (Minimally...
HAART 300 Aortic Annuloplasty Device Sees U.S. Pilot Launch, First Commercial Use
News | Annuloplasty Rings | July 05, 2017
July 5, 2017 — BioStable Science & Engineering Inc.
TITAN II Trial, Carillon Mitral Contour System, Cardiac Dimensions, Open Heart journal, functional mitral regurgitation, FMR
News | Annuloplasty Rings | July 20, 2016
New data from the TITAN II trial confirm the safety and efficacy of the Carillon Mitral Contour System in the treatment...
Mitralign Percutaneous Annuloplasty System, MPAS, CE Mark approval
News | Annuloplasty Rings | April 27, 2016
Mitralign Inc. announced its Mitralign Percutaneous Annuloplasty System (MPAS) has received CE mark approval from its...
Carillon mitral contour system, Cardiac Dimensions, functional mitral regurgitation, FMR, University Hospital Liepzig study
News | Annuloplasty Rings | February 24, 2016
A single-center study noted that treatment with Cardiac Dimensions’ Carillon Mitral Contour System resulted in...
Carillon mitral contour system, cost-effective, optimal medical treatment, OMT, TITAN, functional mitral regurgitation, FMR

Carillon mitral contour system image courtesy of Cardiac Dimensions Inc.

News | Annuloplasty Rings | September 10, 2015
The Carillon mitral contour system is projected to be a cost-effective treatment option when compared to a typical...
Overlay Init